Molecularly targeted therapies for relapsed and refractory peripheral T-cell lymphomas.
Semin Hematol
; 58(2): 78-84, 2021 04.
Article
em En
| MEDLINE
| ID: mdl-33906725
ABSTRACT
The advent of molecularly targeted agents for patients with peripheral T-cell lymphomas (PTCL) has begun to change the therapeutic landscape in these diseases, especially for patients with relapsed or refractory disease. These agents, grounded in targeting numerous pathways or alterations related to disease pathogenesis, have shown promise across many PTCL subhistologies. Aided by significant advances in experimental techniques related to molecular biology, epigenetics, and immunology, more recent studies have begun elucidating mediators of resistance, both intrinsic and acquired, to inform future therapeutic advances. Defining and targeting these escape mechanisms through rational combination approaches will likely be important to continue to build on these promising advances and further improve clinical outcomes for patients facing PTCL.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Temas:
Geral
/
Tipos_de_cancer
/
Outros_tipos
Base de dados:
MEDLINE
Assunto principal:
Linfoma de Células T Periférico
/
Antineoplásicos
Limite:
Humans
Idioma:
En
Revista:
Semin Hematol
Ano de publicação:
2021
Tipo de documento:
Article